No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Approval Alert: FDA Approves J&J’s Darzalex Faspro® (Daratumumab and Hyaluronidase) for Multiple Myeloma
On 30 July 2024, Johnson & Johnson (J&J) announced that the FDA approved Darzalex Faspro® (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) for induction and consolidation in patients with newly...